

## References

---

- Aboagye, A.Q.Q., Degboe, A.N.K. and Obuobi, A.A.D. (2010), 'Estimating the cost of health care delivery in three hospitals in southern Ghana', *Ghana Medical Journal*, **44**, 83–92.
- Aldy, J.E. and Viscusi, W.K. (2007), 'Age differences in the value of statistical life: revealed preference evidence.' *Review of Environmental Economics and Policy*, **1**, 241–60.
- Aldy, J.E. and Viscusi, W.K. (2008), 'Adjusting the value of a statistical life for age and cohort effects', *The Review of Economics and Statistics*, **90**, 573–81.
- Arnesen, T. and Nord, E. (1999), 'The value of DALY life: problems with ethics and validity of disability adjusted life years', *British Medical Journal*, **319**, 1423–5.
- Arrow, K.J. (1950), 'A difficulty in the concept of social welfare', *Journal of Political Economy*, **58**, 328–46.
- Atif, M., Sulaiman, S.A.S., Shafie, A.A., Saleem, F. and Ahmad, N. (2012), 'Determination of chest X-ray cost using activity based costing approach at Penang General Hospital, Malaysia', *Pan African Medical Journal*, **12**, 1–6.
- Au Eong, K.G, Chan, E.W., Luo, N. et al. (2012), 'Validity of EuroQol-5D, time trade-off, and standard gamble for age-related macular degeneration in the Singapore population', *Eye*, **26**, 379–88.
- Auriol, E. and Warlters, M. (2012), 'The marginal cost of public funds and tax reform in Africa', *Journal of Development Economics*, **97**, 58–72.
- Auvert, B., Tjaard, D., Lagarde, E. et al. (2005), 'Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 trial', *PLoS Medicine*, **2**, e298.
- Axnick, N.W., Shavell, S.M. and Witte, J.J. (1969), 'Benefits due to immunization against measles', *Public Health Reports*, **84**, 673–80.
- Baicker, K. and Skinner, J.S. (2011), 'Health care spending growth and the future of US tax rates', *National Bureau of Economic Research Bulletin Aging Health*, **1**, 1–25.
- Baird, S., Hicks, J.H., Kremer, M. and Miguel, E. (2012), 'Worms at work: long-run impacts on child health', working paper, Harvard University, August.
- Ballard, C.L., Shoven, J.B. and Whalley, J. (1985), 'General equilibrium computations of the marginal welfare costs of taxes in the United States', *American Economic Review*, **75**, 128–38.
- Basu, K. and Foster, J.E. (1998), 'On measuring literacy', *Economic Journal*, **108**, 1733–49.
- Bayoumi, A.M. and Redelmeier, D.A. (1999), 'Economic methods for measuring the quality of life associated with HIV infection', *Quality of Life Research*, **8**, 471–80.
- Birch, S. (2004), 'Book reviews: cost–benefit analysis and health care evaluations', *Social Science & Medicine*, **59**, 885–7.

- Binagwaho, A., Pegurri, E., Multa, J. and Bertozzi, S. (2010), 'Male circumcision at different ages in Rwanda: a cost-effectiveness study', *Plos Medicine*, **7**, e1000211.
- Bleichrodt, H. and Johannesson, M. (1997), 'Standard gamble, time trade-off and rating scale: experimental results on the ranking properties of QALYs', *Journal of Health Economics*, **16**, 155–75.
- Bombardier, C., Wolfson, A.D., Sinclair, A.J. et al. (1982), 'Comparisons of three preference measurement methodologies in the evaluation of a functional status index', in D.B. Deber and G.G. Thompson (eds), *Choices in Health Care*, Toronto: Department of Health Administration, University of Toronto.
- Boyle, M.H., Torrance, G.W., Sinclair, J.C. and Horwood, J.C. (1983), 'Economic evaluation of neonatal intensive care of very low birth-weight infants', *New England Journal of Medicine*, **308**, 1300–1307.
- Brent, R.J. (1979), 'Imputing weights behind past railway closure decisions within a cost–benefit framework', *Applied Economics*, **9**, 157–70.
- Brent, R.J. (1980), 'Distinguishing between money income and utility income in cost–benefit analysis', *Public Finance Quarterly*, **8**, 131–52.
- Brent, R.J. (1984a), 'On the use of distributional weights in cost–benefit analysis: a survey of schools', *Public Finance Quarterly*, **12**, 213–30.
- Brent, R.J. (1984b), 'A three objective social welfare function for cost–benefit analysis', *Applied Economics*, **16**, 369–78.
- Brent, R.J. (1986), 'An axiomatic basis for the three objective social welfare functions within a poverty context', *Economics Letters*, **20**, 89–94.
- Brent, R.J. (1989), 'The Farmers Home Administration's social discount rate,' *Applied Economics* **21**, 1247–56.
- Brent, R.J. (1991a), 'A new approach to valuing a life', *Journal of Public Economics*, **44**, 165–71.
- Brent, R.J. (1991b), 'The numbers effect and the shadow wage in project appraisal', *Public Finance*, **46**, 118–27.
- Brent, R.J. (1992), 'The consumption rate of interest and the numbers effect', *Public Finance*, **47**, 367–77.
- Brent, R.J. (1993), 'Country estimates of social discount rates based on changes in life expectancies', *Kyklos*, **46**, 399–409.
- Brent, R.J. (1994a), 'Shadow prices for a physician's services', *Applied Economics*, **26**, 669–76.
- Brent, R.J. (1994b), 'Counting and double-counting in project appraisal', *Project Appraisal*, **9**, 275–81.
- Brent, R.J. (1998a), *Cost–Benefit Analysis for Developing Countries*, Cheltenham, UK and Northampton, MA, USA: Edward Elgar.
- Brent, R.J. (1998b), 'Estimating the effectiveness and benefits of alcohol treatment programmes for use in economic evaluations', *Applied Economics*, **30**, 217–26.
- Brent, R.J. (2002), 'A simple method for converting a cost-effectiveness analysis into a cost–benefit analysis with an application to state mental health expenditures', *Public Finance Review*, **30**, 144–60.
- Brent, R.J. (2003), 'The tax implications of cost shifting in cost–benefit analysis in mental health', *Applied Economics*, **35**, 943–50.
- Brent, R.J. (2004), 'The role of public and private transfers in the cost–benefit analysis of mental health programs', *Health Economics*, **13**, 1125–36.

- Brent, R.J. (2006a), *Applied Cost–Benefit Analysis*, 2nd edn, Cheltenham, UK and Northampton, MA, USA: Edward Elgar.
- Brent, R.J. (2006b), ‘Does female education prevent the spread of HIV/AIDS in sub-Saharan Africa’, *Applied Economics*, **38**, 491–503.
- Brent, R.J. (2008), ‘The role of user fees in the cost–benefit analysis of privatization with an application to hospital psychiatric services in the US’, *Applied Economics*, **40**, 1981–9.
- Brent, R.J. (ed.) (2009a), *Handbook of Research on Cost–Benefit Analysis*, Cheltenham, UK and Northampton, MA, USA: Edward Elgar.
- Brent, R.J. (2009b), ‘A cost–benefit analysis of female primary education as a means of reducing HIV/AIDS in Tanzania’, *Applied Economics*, **41**, 1731–43.
- Brent, R.J. (2009c), ‘A cost–benefit analysis of a condom social marketing program in Tanzania’, *Applied Economics*, **41**, 497–509.
- Brent, R.J. (2010a), *Setting Priorities for HIV/AIDS for HIV/AIDS Interventions: A Cost–Benefit Approach*, Cheltenham, UK and Northampton, MA, USA: Edward Elgar.
- Brent, R.J. (2010b), ‘A social cost–benefit criterion for evaluating voluntary counselling and testing with an application to Tanzania’, *Health Economics*, **19**, 154–72.
- Brent, R.J. (2011), ‘An implicit price of a DALY for use in a cost–benefit analysis of ARVs’, *Applied Economics*, **43**, 1413–21.
- Brent, R.J. (2012a), ‘The effects of HIV medications on the quality of life of older adults in New York City’, *Health Economics*, **21**, 967–76.
- Brent, R.J. (2012b), ‘Treatment: perspectives paper’, in B. Lomborg (ed.), *RethinkHIV: Smarter Ways to Invest in Ending HIV in Sub-Saharan Africa*, Cambridge: Cambridge University Press, Ch. 3.1.
- Brent, R.J. (2013), ‘A cost–benefit framework for evaluating conditional cash-transfer programs’, *Journal of Benefit Cost Analysis*, **4**, 159–80.
- Brent, R.J. (2014), ‘Female education, HIV/AIDS and the education vaccine in sub-Saharan Africa: the condoms piece of the puzzle’, *African Development Review* (forthcoming).
- Brent, R.J. and Patel, M. (1997), ‘Physician rewards for different kinds of service’, *Journal of Plastic and Reconstructive Surgery*, **100**, 51–7.
- Brent, R.J., Brennan, M. and Karpiak, S. (2014), ‘Using a happiness index to measure the benefits for a cost–benefit analysis of antiretrovirals for older adults with HIV in New York City’, *Clinical Research in HIV/AIDS*, **1**(2): 1009, 1–10, 30 August.
- Briggs, A.H. and Gray, A.M. (1998), ‘Power and sample size calculations for stochastic cost-effectiveness analysis’, *Medical Decision Making*, **18**, S81–92.
- Briggs, A.H. and O’Brien, B.J. (2001), ‘The death of cost-minimization analysis’, *Health Economics*, **10**, 179–84.
- Briggs, A., Claxton, K. and Sculpher, M. (2006), *Decision Modelling for Health Economic Evaluation*, New York: Oxford University Press.
- Brown, G.C. (1999), ‘Vision and quality-of-life’, *Transactions of the American Ophthalmological Society*, **97**, 473–511.
- Brown, K. and Burrows, C. (1990), ‘The sixth stool guaiac test, \$47 million that never was’, *Journal of Health Economics*, **9**, 429–45.
- Browning, E.K. and Browning, J.M. (1994), *Public Finance and the Price System*, 4th edn, Englewood Cliffs, NJ: Prentice Hall.

- Buchanan, J.M. and Stubblebine, C. (1962), 'Externality', *Economica*, **29**, 371–84.
- Buchanan, J.M. and Tullock, G. (1962), *The Calculus of Consent*, Ann Arbor, MI: University of Michigan Press.
- Cairns, J.A. and Van Der Pol, M.M. (1997), 'Saving future lives: a comparison of three discounting models', *Health Economics*, **6**, 341–50.
- Canning, D. (2006), 'The economics of HIV/AIDS in low countries: the case for prevention', *Journal of Economic Perspectives*, **20**, 121–42.
- Cartwright, W.S. and Solano, P. (2001), 'The economics of public health: financing drug abuse treatment services', *Health Policy*, **66**, 247–60.
- Chancellor, J.V., Hill, A.H., Sabin, A. et al. (1997), 'Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV Infection', *Pharmacoeconomics*, **12**, 54–66.
- Chang, R.W., Pellissier, J.M. and Hazen, G.H. (1996), 'A cost-effective analysis of total hip arthroplasty for osteoarthritis of the hip', *Journal of the American Medical Association*, **275**, 858–65.
- Chapman, R.H., Stone, P.W., Sandberg, E.A. et al. (2000), 'A comprehensive league table of cost-utility ratios and a sub-table of "Panel-Worthy" Studies', *Medical Decision Making*, **20**, 451–58.
- Churchill, D.N., Torrance, G.W., Taylor, D.W., Barnes, C.C., Ludwin, D., Shimizu, A. and Smith, E.K.M. (1987), 'Measurement of quality of life in end-stage renal disease: the time trade-off approach', *Clinical and Investigative Medicine*, **10**, 14–20.
- Clarke, P.M. (2008), 'Using revealed preference methods to value health – the travel cost approach', in E. McIntosh, P. Clarke, E.J. Frew and J.J. Louviere, *Applied Methods of Cost-Benefit Analysis in Health Care*, Oxford: Oxford University Press, Ch. 9.
- Clarke, R.E., Teague, G.B., Ricketts, S.K., Bush, P.W., Keller, A.M., Zubkoff, M. and Drake, R.E. (1994), 'Measuring resource use in economic evaluations: determining the social costs of mental illness', *The Journal of Mental Health Administration*, **21**, 32–41.
- Clawson, M. (1966), *The Economics of Outdoor Recreation*, Baltimore, MD: Johns Hopkins University Press.
- Claxton, K., Sculpher, M., Culyer, A. et al. (2006), 'Discounting and cost-effectiveness in NICE – stepping back to sort out a confusion', *Health Economics*, **15**, 1–4.
- Clemens, M.A. and Demombynes, G. (2010), 'When does rigorous impact evaluation make a difference?', Policy Research Working Paper No. 5477, Washington, DC: World Bank.
- Coast, J., Flynn, T.N. and Natarajan, L. (2008), 'Valuing the ICECAP Capability Index for older people', *Social Science and Medicine*, **67**, 874–82.
- Conley, B.C. (1976), 'The value of human life in the demand for safety', *American Economic Review*, **66**, 45–55.
- Cook, J., Richardson, J. and Street, A. (1994), 'A cost utility analysis of treatment options for gallstone disease, methodological issues and results', *Health Economics*, **3**, 157–68.
- Cookson, R. (2005), 'QALYs and the capability approach', *Health Economics*, **14**, 817–29.
- Craig, B.M. (2009), 'The duration effect: a link between TTO and VAS values', *Health Economics*, **18**, 217–25.
- Cullis, J.G. and Jones, P.G. (1986), 'Rationing by waiting lists: an implication', *American Economic Review*, **74**, 250–56.

- Culyer, A.J. (1982), 'Health care and the market, a British lament', *Journal of Health Economics*, **1**, 299–303.
- Cutler, D. and Glaeser, E. (2005), 'What explains the differences in smoking, drinking and other health-related behaviors?', *American Economic Review*, **95**, 238–42.
- Dageforde, L.A., Moore, D.R., Landman, M.P. et al. (2012), 'Comparison of open live donor nephrectomy, laparoscopic live donor nephrectomy, and hand-assisted live donor nephrectomy: a cost-minimization analysis', *Journal of Surgical Research*, **30**, E1–E6.
- Deaton, A. (2010), 'Instruments, randomization and learning about development', *Journal of Economic Literature*, **48**, 424–55.
- Demombynes, G. and Trommlerova, S.K. (2012), 'What has driven the decline of infant mortality in Kenya? Policy Research Working Paper No. 6057, Washington, DC: World Bank.
- Devlin, N. and Parkin, D. (2004), 'Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis', *Health Economics*, **13**, 437–52.
- Dickey, B., Fisher, W., Siegel, C. et al. (1997), 'The cost and outcomes of community-based care for the seriously mentally ill', *Health Services Research*, **32**, 599–614.
- Dolan, P. (1997), 'Modeling valuations for EuroQol health states', *Medical Care*, **35**, 1095–108.
- Dolan, P. (1998), 'The measurement of individual utility and social welfare', *Journal of Health Economics*, **17**, 39–52.
- Dolan, P. and Green, C. (1998), 'Using the person trade-off approach to examine differences between individual and social values', *Health Economics*, **7**, 307–12.
- Dolders, M.G.T., Zeegers, M.P.A., Groot, W. et al. (2006), 'A meta-analysis demonstrates no significant differences between patient and population preferences', *Journal of Clinical Epidemiology*, **59**, 653–64.
- Donaldson, C. (1990), 'Willingness to pay for publicly-provided goods: a possible measure of benefit?', *Journal of Health Economics*, **9**, 103–18.
- Donaldson, C. (1999), 'Valuing the benefits of publicly-provided health care: does "ability to pay" preclude the use of "willingness to pay"?'', *Social Science and Medicine*, **49**, 551–63.
- Doubilet, P., Weinstein, M.C. and McNeil, B.J. (1986), 'Use and misuse of the term "cost-effective" in medicine', *New England Journal of Medicine*, **314**, 253–6.
- Dowie, J. (1998), 'Towards the equitably efficient and transparently decidable use of public funds in the deep blue millennium', *Health Economics*, **7**, 93–103.
- Dranove, D. (1995), 'Measuring costs', in F.A. Sloan (ed.), *Valuing Health Care*, New York: Cambridge University Press, pp. 61–75.
- Drummond, M.F. (1981), 'Welfare economics and cost-benefit analysis in health care', *Scottish Journal of Political Economy*, **28**, 125–45.
- Drummond, M.F. (1990), 'Priority setting for AIDS and other health care programmes', in M.F. Drummond and L.M. Davies (eds), *AIDS: The Challenge for Economic Analysis*, Birmingham: Health Services Management Centre in collaboration with the WHO.
- Drummond, M.F., Stoddart, G.L. and Torrance, G.W. (1987), *Methods for Economic Evaluation of Health Care Programmes*, New York: Oxford University Press.

- Drummond, M.F., Sculpher, M.J., Torrance, G.W., O'Brien, B.J. and Stoddart, G.L. (2005), *Methods for Economic Evaluation of Health Care Programmes*, 3rd edn, Oxford: Oxford University Press.
- Drummond, M., Torrance, G. and Mason, J. (1993), 'Cost-effectiveness league tables: more harm than good', *Social Science and Medicine*, **37**, 33–40.
- Eddy, D.M. (1991a), 'Oregon's methods. Did cost-effectiveness analysis fail?', *Journal of the American Medical Association*, **266**, 2135–41.
- Eddy, D.M. (1991b), 'Oregon's methods. Should it be approved?', *Journal of the American Medical Association*, **266**, 2439–45.
- Elamin, E.I., Ibrahim, M.I.M., Sulaiman, S.A.S. and Muttalif, A.R. (2008), 'Cost of illness of tuberculosis in Penang, Malaysia', *Pharmacy World and Science*, **30**, 281–6.
- Elixhauser, A., Luce, B.R., Taylor, W.R. and Reblando, J. (1993), 'Health care CBA/CEA, an update on the growth and composition of the literature', *Medical Care*, **31**, JS1–JS11.
- Epstein, J.F. and Grfeorer, J.C. (1995), 'A method for estimating substance abuse treatment need from a National Household Survey', paper presented at the Thirty-seventh International Congress on Alcohol and Drug Dependence, University of California at San Diego, 20–25 August.
- Fingarette, H. (1988), *Heavy Drinking*, Berkeley, CA: University of California Press.
- Finkler, S.A. (1982), 'The distinction between cost and charges', *Annals of Internal Medicine*, **96**, 102–9.
- Flynn, T.N., Chan, P., Coast, J. et al. (2011), 'Assessing quality of life among British older people using the ICEPOP CAPability (ICECAP-O) measure', *Applied Health Economics and Health Policy*, **9**, 317–29.
- Forester, T.H., McNowan, R.F. and Singell, L.D. (1984), 'A cost-benefit analysis of the 55 mph speed limit', *Southern Economic Journal*, **50**, 631–41.
- Frank, R.G. (1991), 'Clozapines cost-benefits' [letter], *Hospital and Community Psychiatry*, **42**, 92.
- French, M.T., Mauskopf, J.A., Teague, J.L. And Roland, E.J. (1996), 'Estimating the dollar value of health outcomes from drug abuse interventions', *Medical Care*, **34**, 890–910.
- French, M.T., Popovici, I. and Tapsell, B.A. (2008), 'The economic costs of substance abuse treatment: updated estimates and cost bands for program assessment and reimbursement', *Journal of Substance Abuse and Treatment*, **35**, 462–9.
- Fryback, D.G., Dasbach, E.J. and Klein, R. (1993), 'The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors', *Medical Decision Making*, **13**, 89–102.
- Garbacz, C. and Thayer, M.A. (1983), 'An experiment in valuing senior companion program services', *Journal of Human Resources*, **18**, 147–53.
- Garber, A.M. and Phelps, C.E. (1997), 'economic foundations of cost-effectiveness analysis', *Journal of Health Economics*, **16**, 1–31.
- Gardiner, J., Hogan, A., Holmes-Rovner, M., Rovner, D., Griffith, L. and Kupersmith, J. (1995), 'Confidence intervals for cost-effectiveness ratios', *Medical Decision Making*, **15**, 254–63. Gatsonis, C. (1990), 'The long debate on the sixth stool guaiac test, time to move on to new grounds', *Journal of Health Economics*, **9**, 495–7.

- Gerard, K. and Mooney, G. (1993), 'QALY league tables: handle with care', *Health Economics*, **2**, 59–64.
- Gertler, P.J., Locay, L. and Sanderson, W. (1987), 'Are user fees regressive? The welfare implications of health care financing proposals in Peru', *Journal of Econometrics*, **36**, 67–88.
- Getzen, T.E. (1997), *Health Economics, Fundamentals and Flow of Funds*, New York: John Wiley & Sons.
- Ghana Health Assessment Project Team (1981), 'A quantitative method of assessing the health impact of different diseases in less developed countries', *International Journal of Epidemiology*, **10**, 73–80.
- Gold, M.R., Siegel, J.E., Russell, L.B. and Weinstein, M.C. (1996), *Cost-Effectiveness in Health and Medicine*, New York: Oxford University Press.
- Grewal, I., Lewis, J., Flynn, T.N. et al. (2006), 'Developing attributes for a generic quality of life measure for older people; preferences or capabilities', *Social Science and Medicine*, **62**, 1891–901.
- Grob, G.N. (1994), 'Government and mental health policy: a structural analysis', *Millbank Quarterly*, **72**, 471–500.
- Gruber, J. (2002–03), 'Smoking's externalities', *Regulation*, **25**, 52–7.
- Gruber, J. and Mullainathan, S. (2002), 'Do cigarette taxes make smokers happier?', NBER Working Paper No. 8872, April, National Bureau of Economic Research, Cambridge, MA.
- Grutters, J.P.C., Joore, M.A., van der Horst, F. et al. (2007), 'Choosing between measures: comparison of EQ-5D, HUI2 and HUI3 in persons with hearing complaints', *Quality of Life Research*, **16**, 1439–49.
- Guinness, L., Kumaranayake, L., Bhuvanewari, R. et al. (2005), 'Does scale matter? The costs of HIV-prevention interventions for commercial sex workers in India', *Bulletin of the World Health Organization*, **83**, 747–55 and A–F.
- Gyrd-Hansen, D. (2003), 'Willingness to pay for a QALY', *Health Economics*, **12**, 1049–60.
- Haacker, M. (2006), 'When you are talking a possible \$1,000 a day tax-free, it's real attractive', paper presented at the Annual Meeting of the European Economic Association, Vienna.
- Hadley, J. (1991), 'Theoretical and empirical foundations of the resource-based relative value scale', H.E. Frech III (ed.), *Regulating Doctors' Fees: Competition, Benefits, and Controls under Medicare*, Washington, DC: AEI Press, Ch. 5.
- Hadorn, D.C. (1991), 'Setting health care priorities in Oregon. Cost-effectiveness analysis meets the rule of reason', *Journal of the American Medical Association*, **265**, 2218–25.
- Hannum, R.J. (1997), 'Using an expected utility model to analyze the social costs and benefits of childhood immunizations', PhD thesis, Department of Economics, Fordham University, New York.
- Harberger, A. (1978), 'On the use of distributional weights in social cost-benefit analysis', *Journal of Political Economy*, **86**, S87–S120.
- Hargreaves, J.R., Bonell, P., Boler, T. et al. (2008), 'Systematic review exploring time trends in the association between educational attainment and risk of HIV infection in sub-Saharan Africa', *AIDS*, **22**, 403–14.

- Harper, D.R. (1979), 'Disease costing in a surgical ward', *British Medical Journal*, **1**, 647–9.
- Harris, J. (1985), *The Value of Life: An Introduction to Medical Ethics*, London: Routledge.
- Hauber, A.B. (2009), 'Healthy-years equivalent: wounded but not yet dead', *Expert Review of Pharmacoeconomics and Outcomes Research*, **9**, 265–29.
- Heal, G.M. (1998), *Valuing the Future: Economic Theory and Sustainability*, New York: Columbia University Press.
- Hellinger, F.J. (1993), 'The lifetime cost of treating a person with HIV', *Journal of the American Medical Association*, **270**, 474–8.
- Hinman, A.R. and Koplan, J.P. (1984), 'Pertussis and pertussis vaccine, reanalysis of benefits, risks and costs', *Journal of the American Medical Association*, **251**, 3109–13.
- Hirth, R.A., Chernew, M.E., Miller, E., Fendrick, M. and Weissert, W.G. (2000), 'Willingness to pay for a quality-adjusted life year: in search for a standard', *Medical Decision Making*, **20**, 332–42.
- H.M. Treasury (2003), *The Green Book: Appraisal and Evaluation in Central Government*, London: TSO.
- Hoch, J.S., Rockx, M.A. and Hrahn, A.D. (2006), 'Using the net-benefit regression framework to construct cost-effectiveness acceptability curves: an example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of 'community acquired' syncope', *BMC Health Services Research*, **6**, doi: 10.1186/1472-6963-6-68.
- Hochman, H.M. and Rodgers, J.D. (1971), 'Is efficiency a criterion for judging redistribution?', *Public Finance*, **26**, 76–98.
- Hoffmann, V., Barrett, C.B. and Just, D.R. (2009), 'Do free goods stick to poor households? Experimental evidence on insecticide treated bednets', *World Development*, **37**, 607–17.
- Horngren, C.T. (1982), *Cost Accounting*, 5th edn, Englewood Cliffs, NJ: Prentice-Hall.
- Horowitz, J.K. and McConnell, K.E. (2002), 'A review of WTA/WTP studies', *Journal of Environmental Economics and Management*, **44**, 426–47.
- Horsman, T., Furlong, W., Feeny, D. and Torrance, G. (2003), 'The Health Utilities Index (HUI): concepts, measurement properties and applications', *Health and Quality of Life Outcomes*, **1**, 54, doi: 10.1186/1477-7525-1-54
- Hounton, S. and Newlands, D. (2012), 'Applying the net-benefit framework for analyzing and presenting cost-effectiveness analysis of a maternal and newborn health intervention', *PLoS ONE*, **7**, e40995, doi: 10.1371.
- Hsiao, W.C. and Dunn, D.L. (1991), 'The Resource-Based Relative Value Scale for pricing physicians' services', in H.E. Frech (ed.), *Regulating Doctors' Fees, Competition, Benefits, and Controls under Medicare*, Washington, DC: AEI Press, Ch. 9.
- Hsiao, W.C., Braun, P., Kelly, N.L. and Becker, E.R. (1988), 'Results, potential effects, and implementation issues of the Resource-Based Relative Value Scale', *Journal of the American Medical Association*, **260**, 2429–38.
- Hull, R., Hirsh, J., Sackett, D.L. and Stoddart, G. (1981), 'Cost effectiveness of clinical diagnosis, venography, and noninvasive testing in patients with symptomatic deep-vein thrombosis', *New England Journal of Medicine*, **304**, 1561–7.
- Hurley, S., Kaldor, J.M., Gardiner, S., Carlin, J.B., Assuncao, R.M. and Evans, D.B. (1996),



- 'Lifetime cost of human immunodeficiency virus-related health care', *Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology*, **12**, 371–8.
- Hyder, A.A. and Morrow, R.H. (1999), 'Steady state assumptions in DALYs: Effect on estimates of HIV impact', *Journal of Epidemiology and Community Health*, **53**, 43–5.
- Hyder, A.A., Rotllant, G. and Morrow, R.H. (1998), 'Measuring the burden of disease: healthy life-years', *American Journal of Public Health*, **88**, 196–202.
- Institute for Health Metrics and Evaluation (2013), *The Global Burden of Disease: Generating Evidence, Guiding Policy*, Seattle, WA: IHME.
- Jari, J., Gerdtham, U.-G., Ludbrook, A. and Petrie, D. (2010), 'On measurement of avoidable and unavoidable cost of alcohol: an application of method for estimating costs due to prior consumption', *International Journal of Environmental Research and Public Health*, **7**, 2881–95.
- Jerrell, J.M. and Hu, T.-W. (1989), 'Cost-effectiveness of intensive clinical and case management compared with an existing system of care', *Inquiry*, **26**, 224–34.
- Jofre-Bonet, M. and Petry, N.M. (2008), 'Trading apples for oranges? Results of an experiment on the effects of heroin and cocaine price changes on addicts' polydrug use', *Journal of Economic Behavior and Organization*, **66**, 281–311.
- Johannesson, M. (1999), 'On aggregating QALYs: a comment on Dolan', *Journal of Health Economics*, **18**, 381–6.
- Johannesson, M. and Gerdtham, U.-G. (1996), 'A note on the estimation of the equity–efficiency trade-off for QALYs', *Journal of Health Economics*, **15**, 359–68.
- Johannesson, M. and Johannsson, P.-O. (1997), 'Is the valuation of a QALY gained independent of age? Some empirical evidence', *Journal of Health Economics*, **16**, 589–99.
- Johar, M.A., Jones, G.S. and Savage, E. (2013), 'Emergency admissions and elective surgery waiting times', *Health Economics*, **22**, 749–56.
- Kahneman, D. and Tversky, A. (1979), 'Prospect theory: an analysis of decision under risk', *Econometrica*, **47**, 263–91.
- Kaplan, R.M. (1995), 'Utility assessment for estimating quality-adjusted life years', in F.A. Sloan (ed.), *Valuing Health Care*, New York: Cambridge University Press, pp. 31–60.
- Kaplan, R.M. and Bush, J.W. (1982), 'Health related quality of life measurement for evaluation research and policy analysis', *Health Psychology*, **1**, 61–80.
- Kaplan, R.M., Bush, J.W. and Berry, C.C. (1979), 'Health Status Index', *Medical Care*, **17**, 501–25.
- Keeler, E.B. and Cretin, S.B. (1983), 'Discounting of life-saving and other non-monetary effects', *Management Science*, **29**, 300–306.
- Khandker, S.R., Koolwal, G.B. and Samad, H.A. (2010), *Handbook on Impact Evaluation: Quantitative Methods and Practices*, Washington, DC: World Bank.
- Kind, P., Rosser, R.M. and Williams, A.H. (1982), 'Valuations of quality of life: some psychometric evidence', in M.W. Jones-Lee (ed.), *The Value of Life and Safety*, Amsterdam: North Holland, pp. 159–70.
- Klarman, H.E. (1965), 'Syphilis control programs', in R. Dorfman (ed.), *Measuring Benefits of Government Investments*, Washington, DC: Brookings Institution, pp. 367–414.
- Klarman, H.E. (1982), 'The road to cost-effectiveness analysis', *Milbank Memorial Fund Quarterly*, **60**, 1–16.

- Klarman, H.E., Francis, J. and Rosenthal, G. (1968), 'Cost-effectiveness applied to the treatment of chronic renal disease', *Medical Care*, **6**, 48–54.
- Klevit, H.D., Bates, A.C., Castanares, T., Kirk, E.P., Sipes-Metzler, P.R. and Wopat, R. (1991), 'Prioritization of health care services. a progress report by the Oregon Health Services Commission', *Archives of Internal Medicine*, **151**, 912–16.
- Kniesner, T.J., Viscusi, W.K. and Zilak, J.P. (2012), 'Willingness to accept equals willingness to pay for labor market estimates of the value of statistical life', Discussion Paper No. 6816, August, Institute for the Study of Labor (IZA), Bonn.
- Koplan, J.P. and Preblud, S.R. (1982), 'A benefit-cost analysis of mumps vaccine', *American Journal of Diseases in Children*, **136**, 362–4.
- Koplan, J.P., Schoenbaum, S.C., Weinstein, M.C. and Fraser, D.W. (1979), 'Pertussis vaccine, an analysis of benefits, risks and costs', *New England Journal of Medicine*, **301**, 906–11.
- Kremer, M. (1994), 'Can having fewer partners increase prevalence of AIDS?', NBER Working Paper No. 4942, National Bureaus of Economic Research, Cambridge, MA.
- Kristensen, T., Olsen, K.R., Kilsmark J., Lauridsen, J.T. and Pedersen, K.M. (2012), 'Economies of scale and scope in the Danish hospital sector prior to radical restructuring plans', *Health Policy*, **106**, 120–26.
- Kuklys, W. (2005), *Amartya Sen's Capability Approach*, Berlin: Springer.
- Lasker, E.M., Meisner, M. and Siegel, C. (1997), 'Statistical inference for cost-effectiveness ratios', *Health Economics*, **6**, 229–42.
- Lie, R.K. and Miller, F.G. (2011), 'What counts as reliable evidence for public health policy: the case of circumcision for preventing HIV infection', *BMC Medical Research Methodology*, **11**, 34, doi: 10.1186/1471-2288-11-34.
- Lindelow, M. (2008), 'Health as a family matter: do intra-household education externalities matter for maternal and child health?', *Journal of Development Studies*, **44**, 562–85.
- Lindsay, C.M. and Feigenbaum, B. (1984), 'Rationing by waiting lists', *American Economic Review*, **74**, 405–17.
- Linnerooth, J. (1979), 'The value of life: a review of the models', *Economic Inquiry*, **17**, 52–74.
- Llewellyn-Thomas, H., Sutherland, H.J., Tibshiranu, R. et al. (1984), 'Describing health states. Methodological issues in obtaining values for health states', *Medical Care*, **22**, 543–52.
- Logan, A.G., Milne, B.J., Achber, R.N., Campbell, W.P. and Haynes, R.B. (1981), 'Cost-effectiveness of a worksite hypertension treatment program', *Hypertension*, **3**, 211–18.
- Lomborg, B. (ed.) (2012), *RethinkHIV: Smarter Ways to Invest in Ending HIV in Sub-Saharan Africa*, Cambridge: Cambridge University Press.
- Lorgelly, P., Lawson, K.D., Fenwick, E.A.L. et al. (2010), 'Outcome measurement in Economic Evaluations of Public Health Interventions: A Role for the Capability Approach?', *Environmental Research and Public Health*, **7**, 2274–89.
- Mainardi, S. (2003), 'Social welfare objectives and distribution weights in public health planning in Turkey', *Journal of Studies in Economics and Econometrics*, **27**, 29–47.
- Makai, P., Brouwer W.B.F., Koopmanschap, M. et al. (2012), 'Capabilities and quality of life in Dutch psycho-geriatric nursing homes: an exploratory study using a proxy version of the ICECAP-O', *Quality of Life Research*, **21**, 801–12.
- Makai, P., Koopmanschap, M.A., Brouwer W.B.F. et al. (2013), 'A validation of the

- ICECAP-O in a population of post-hospitalized older people in the Netherlands', *Health and Quality of Life Outcomes*, **11**, 57.
- Maloney, S., Jolly, B., Sims, J. et al. (2012), 'Breakeven, cost benefit, cost effectiveness, and willingness to pay for web-based versus face-to-face education delivery for health professionals', *Journal of Medical Internet Research*, **14**, e47, doi: 10.2196/jmir.2040.
- Martin, S. and Smith, P. (1999), 'Rationing by waiting lists: an empirical investigation', *Journal of Public Economics*, **71**, 141–64.
- Mason, H., Jones-Lee, M. and Donaldson, C. (2009), 'Modeling the monetary value of a QALY: a new approach based on UK data.' *Health Economics*, **18**, 933–50.
- Maynard, A. (1991), 'Developing the Health Care Market', *The Economic Journal*, **101**, 1277–86.
- McCollister, K.E., French, M.T., Pyne, J., Booth, B., Rapp, R. and Carr C. (2009), 'The cost of treating addiction from the client's perspective: results from a multi-modality application of the client DATCAP', *Drug and Alcohol Dependence*, **104**, 243–8.
- Mehrez, A. and Gafni, A. (1989), 'Quality-adjusted life years, utility theory, and healthy-years equivalents', *Medical Decision Making*, **9**, 142–9.
- Meltzer, H.Y., Cola, P., Way, L., Thompson, P.A., Bastani, B., Davies, M.A. and Switz, B. (1993), 'Cost-effectiveness of clozapine in neuroleptic-resistant schizophrenia', *American Journal of Psychiatry*, **150**, 1630–8.
- Miguel, E. and Kremer, M. (2004), 'Worms identifying impacts on education and health in the presence of treatment externalities', *Econometrica*, **72**, 159–217.
- Miller, T.R. (2000), 'Variations between countries in values of statistical life.' *Journal of Transport Economics and Policy*, **34**, 169–88.
- Mishan, E.J. (1982), *Cost–Benefit Analysis*, 3rd edn, London: George Allen and Unwin.
- Moore, M.A., Boardman, A.E. and Vining, A.R. (2013), 'More appropriate discounting: the rate of social time preference and the value of the social discount rate', *Journal of Benefit Cost Analysis*, **4**, 1–16.
- Moore, M.J. and Viscusi, W.K. (1988a), 'The quantity-adjusted value of life', *Economic Inquiry*, **26**, 369–88.
- Moore, M.J. and Viscusi, W.K. (1988b), 'Doubling the estimated value of life: results using new occupational fatality data', *Journal of Policy Analysis and Management*, **7**, 476–90.
- Morimoto, T. and Fukui, T. (2002), 'Utilities measured by rating scale, time trade-off, and standard gamble: review and reference for health care professionals', *Journal of Epidemiology*, **12**, 160–78.
- Murray, C.J.L. and Acharya, A.K. (1997), 'Understanding DALYs', *Journal of Health Economics*, **16**, 703–30.
- Murray, C.J.L. and Lopez, A.D. (1996), *The Global Burden of Disease. A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020*, Cambridge: Harvard University Press.
- Musgrove, P. (1992), 'Cost–benefit analysis of a regional system for vaccination against pneumonia, meningitis type B, and typhoid fever', *Bulletin of the Pan American Health Organization*, **26**, 173–91.
- National Highway Safety Administration (2012), *Traffic Safety Facts: Research Note*, February 2012. US Department of Transportation, Washington, DC.
- National Institute for Health and Clinical Excellence (NICE) (2008), 'Guide to the

- methods of technology appraisal', available at: [www.nice.org.uk](http://www.nice.org.uk) (accessed 10 June 2014).
- Natrass, N. (2012), 'Strengthening health systems: perspectives paper', in B. Lomborg (ed.), *RethinkHIV: Smarter Ways to Invest in Ending HIV in Sub-Saharan Africa*, Cambridge: Cambridge University Press, Ch. 4.2.
- Neuhauser, D. (1990), 'The sixth stool guaiac test, a reply', *Journal of Health Economics*, **9**, 493–4.
- Neuhauser, D. and Lewicki, M. (1975), 'What do we gain from the sixth stool guaiac?', *New England Journal of Medicine*, **293**, 226–8.
- Nord, E. (1992), 'Methods for quality adjustment of life years', *Social Science and Medicine*, **34**, 559–69.
- Nord, E. (1993), 'The trade-off between severity of illness and treatment effect in cost-value analysis of health care', *Health Policy*, **24**, 227–38.
- Nord, E. (1995), 'The person-trade-off approach to valuing health care programs', *Medical Decision Making*, **15**, 201–8.
- Nord, E., Pinto, J.P., Richardson, J., Menzel, P. and Ubel, P. (1999), 'Incorporating societal concerns for fairness in numerical valuations of health programmes', *Health Economics*, **8**, 25–39.
- O'Brien B.J. and Briggs, A.H. (2002), 'Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods', *Statistical Methods in Medical Research*, **11**, 455–68.
- O'Brien, B.J., Drummond, M.F., Labelle, R.J. and Willan, A. (1994), 'In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care', *Medical Care*, **32**, 150–63.
- O'Brien, B.J., Gertsen, K., Willan, A.R. and Faulkner, L.A. (2002), 'Is there a kink in consumers' threshold value for cost-effectiveness in health care?', *Health Economics*, **11**, 175–80.
- Olsen, J.A. (1994), 'Person vs years: two ways of eliciting implicit weights', *Health Economics*, **3**, 39–46.
- Olsen, J.A. and Donaldson, C. (1998), 'helicopters, hearts and hips: using willingness to pay to set priorities for public sector health care programmes', *Social Science and Medicine*, **46**, 1–12.
- Oregon Health Services Commission (2009), *Prioritization of Health Services*, Office for Oregon Policy and Research, Department of Human Services. A Report to the Governor and the Seventy-fifth Oregon Legislative Assembly.
- Oster, E. (2005), 'Sexually transmitted infections, sexual behavior, and the HIV/AIDS epidemic.' *Quarterly Journal of Economics*, **70**, 467–515.
- Overlander, J., Marmor, J. and Jacobs, L. (2001), 'Rationing medical care: rhetoric and reality in the oregon health plan', *Canadian Medical Association Journal*, **164**, 1583–7.
- Patrick, D.L., Bush, J.W. and Chen, M.M. (1973), 'Methods for measuring well-being for a health status index', *Health Services Research*, **8**, 228–45.
- Pauly, M.V. (1995), 'Valuing health care benefits in money terms', in F.A. Sloan (ed.), *Valuing Health Care*, New York: Cambridge University Press, pp. 99–124.
- Peabody, J.W., Rahman, M.O., Gertler P.J. et al. (1999), *Policy and Health: Implications for Development in Asia*, Cambridge: Cambridge University Press.

- Peto, R., Collins, R. and Gray, R. (1995), 'Large-scale randomized evidence: large, simple trials and overviews of trials', *Journal of Clinical Epidemiology*, **48**, 23–40.
- Phelps, C.E. (1988), 'Death and taxes', *Journal of Health Economics*, **7**, 1–24.
- Philipson, T. and Posner, R. (1993), *Private Choices and Public Health: The AIDS Epidemic in an Economic Perspective*, Cambridge, MA: Harvard University Press.
- Pigou, A.C. (1920), *The Economics of Welfare*, London: Macmillan.
- Pisani, E. (2008), *The Wisdom of Whores: Bureaucrats, Brothels and the Business of AIDS*. New York: W.W. Norton & Company.
- Pizer, S.D. and Prentice, J.C. (2011), 'Time is money: outpatient waiting times and health insurance choices of elderly veterans in the United States', *Journal of Health Economics*, **30**, 626–36.
- Politi, C., Carrin, G., Evans, D., Kuzoe, F.A.S. and Cattand, P.D. (1995), 'Cost-effectiveness analysis of alternative treatments of African gambiense trypanosomiasis in Uganda', *Health Economics*, **4**, 273–87.
- Propper, C. (1990), 'Contingent valuation of time spent on NHS waiting lists', *Economic Journal*, **100**, 193–9.
- Rabin, R., Oemar, M. and Oppe, M. (2011), *EQ-5D-3L User Guide: Basic Information on How to Use the EQ-5D-3L Instrument*, Version 4.0, Rotterdam: EuroQol Group.
- Ravens-Sieberer, U., Wille, N., Badia, X. et al. (2010), 'Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study', *Quality of Life Research*, **19**, 887–97.
- Read, J.L., Quinn R.J., Berwick, D.M. et al. (1984), 'Preferences for health outcomes. comparison of assessment methods', *Medical Decision Making*, **4**, 315–29.
- Revicki, D.A., Luce, B.R., Wechsler, J.M., Brown, R.E. and Adler, M.A. (1990), 'Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients', *Hospital and Community Psychiatry*, **41**, 870–4.
- Rice, D.P., Kelman, S. and Miller, L.S. (1992), 'The economic burden of mental illness', *Hospital and Community Psychiatry*, **43**, 1227–32.
- Richardson, J., Hall, J. and Salkeld, G. (1989), 'Cost utility analysis: the compatibility of measurement techniques and the measurement of utility through time', in S.C. Smith (ed.), *Economics and Health*, proceedings of the Eleventh Australian Conference of Health Economists, Monash University, Clayton, Victoria.
- Ried, W. (1998), 'QALYs versus HYE's – what's right and what's wrong. a review of the controversy', *Journal of Health Economics*, **17**, 607–25.
- Robinson, L.A. (2007), 'How US government agencies value mortality risk reductions', *Review of Environmental Economics and Policy*, **1**, 283–99.
- Robinson, S. (2011), 'Test-retest reliability of health state valuation techniques: the time trade off and person trade off', *Health Economics*, **20**, 1379–91.
- Roebuck, C., French, M.T. and McLellan, T. (2003), 'DATStats: results from 85 studies using the Drug Abuse Treatment Cost Analysis Program (DATCAP)', *Journal of Substance Abuse Treatment*, **25**, 51–7.
- Roehrborn, C.G. and Black, L.K. (2011), 'The economic burden of prostate cancer', *British Journal of Urology International*, **108**, 806–13.
- Rosser, R. and Kind, P. (1978), 'A scale of valuations of states of illness: is there a social consensus?', *International Journal of Epidemiology*, **7**, 347–58.
- Russell, L.B., Gold, M.R., Siegel, J.E., Daniels, N. and Weinstein, M.C. (1996), 'The role

- of cost-effectiveness analysis in health and medicine', *Journal of the American Medical Association*, **276**, 1172–7.
- Ryan, M. (1999), 'Using conjoint analysis to take account of patient preferences and go beyond outcomes: an application to in vitro fertilization', *Social Science and Medicine*, **48**, 535–46.
- Ryan, M. and Hughes, J. (1997), 'Using conjoint analysis to assess women's preferences for miscarriage management', *Health Economics*, **6**, 261–73.
- Sabik, L.M. and Lie, R.K. (2008), 'Priority setting in health care: lessons from the experiences of eight countries', *International Journal for Equity in Health*, **7**, 1–13.
- Sachs, J.D. (2005), *The End of Poverty*, New York: Penguin Press.
- Sackett, D.L. and Torrance, G.W. (1978), 'The utility of different health states as perceived by the general public', *Journal of Chronic Diseases*, **31**, 697–704.
- Samuelson, P.A. (1954), 'The pure theory of public expenditure', *Review of Economics and Statistics*, **36**, 350–6.
- Scharff, R.L. (2009), 'Obesity and hyperbolic discounting: evidence and implications', *Journal of Consumer Policy*, **32**, 3–21.
- Schimmel, V.E., Alley, C. and Heath, A.M. (1987), 'Measuring costs, product line accounting versus ratio of cost to charges', *Journal of Health Care Finance*, **13**, 76–86.
- Sen, A. (1985), *Commodities and Capabilities*, New York: Elsevier.
- Shillcutt, S.D., Walker, D.G., Goodman, C.A. and Mills, A.J. (2010), 'Cost-effectiveness in low and middle-income countries: a review of the debates surrounding decision rules', *Pharmacoeconomics*, **27**, 903–17.
- Shiroiwa, T., Sung, Y-K, Y., Fukuda, T. et al. (2010), 'International Survey on Willingness to Pay (WTP) for One Additional QALY Gained: What is the Threshold of Effectiveness?', *Health Economics*, **19**, 422–437.
- Shwartz, M., Young, D.W. and Siegrist, R. (1995), 'The ratio of costs to charges, how good a basis for estimating costs?', *Inquiry*, **32**, 476–81.
- Siegel, C., Laska, E.M. and Meisner, M. (1996), 'Statistical methods for cost-effectiveness analysis', *Controlled Clinical Trials*, **17**, 387–406.
- Siegel, J.E., Weinstein, M.C., Russell, L.B. and Gold, M.R. (1996), 'Recommendations for reporting cost-effectiveness analyses', *Journal of the American Medical Association*, **276**, 1339–41.
- Siraprapasiri, T., Sawaddiwudhipong, W. and Rojanasuphot, S. (1997), 'Cost benefit analysis of Japanese encephalitis vaccination program in Thailand', *The Southeast Journal of Tropical Medicine and Public Health*, **28**, 143–8.
- Sonnenberg, F.A. and Beck, J.R. (1993), 'Markov models in medical decision making: a practical guide', *Medical Decision Making*, **13**, 322–38.
- Squire, L. and van der Tak, H. (1975), *Economic Analysis of Projects*, Baltimore, MD: Johns Hopkins University Press.
- Starmer, C. (2000), 'Developments in non-expected utility theory: the hunt for a descriptive theory of choice under risk', *Journal of Economic Literature*, **38**, 332–82.
- Stason, W.B. and Weinstein, M.C. (1977), 'Allocation of resources to manage hypertension', *New England Journal of Medicine*, **296**, 732–9.
- Stern, S.H., Singer, L.B. and Weissman, M.M. (1995), 'Analysis of hospital cost in total knee arthroplasty', *Clinical Orthopaedics and Related Research*, **321**, 36–44.

- Stillwaggon, E. (2006), *AIDS and the Ecology of Poverty*. New York: Oxford University Press.
- Tarride, J.-E., Lim, M.E., Bowen, J.M. et al. (2009), 'In Search of the Evidentiary Foundation of Published Canadian Economic Evaluation (2001–2006)', *International Journal of Technology Assessment in Health Care*, **25**, 214–221.
- Temin, P. (1983), 'Costs and benefits in switching drugs from Rx to OTC', *Journal of Health Economics*, **2**, 187–205.
- Tengs, T. and Lin, T.H. (2002), 'A meta-analysis of utility estimates for HIV/AIDS', *Medical Decision Making*, **22**, 475–81.
- Thaler, R. and Rosen, S. (1975), 'The value of saving a life: evidence from the labor market', in N. Terleckyj (ed.), *Household Production and Consumption*, New York: NBER, pp. 265–302.
- Thavorncharoensap, M., Teerawattananon, Y., Natant, S. et al. (2013), 'Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?', *ClinicoEconomics and Outcomes Research*, **5**, 29–36.
- Thompson, M.S., Read, J.S. and Liang, M. (1984), 'Feasibility of willingness to pay measurement in chronic arthritis', *Medical Decision Making*, **4**, 195–215.
- Torrance, G.W. (1976), 'Social preferences for health states: an empirical evaluation of three measurement techniques', *Socio-Economic Planning Sciences*, **10**, 129–36.
- Torrance, G.W. (1986), 'Measurement of health state utilities for economic appraisal', *Journal of Health Economics*, **5**, 1–30.
- Torrance, G.W. and Feeny, D. (1989), 'Utilities and quality-adjusted life years', *International Journal of Technology Assessment in Health Care*, **5**, 559–75.
- Torrance, G.W., Boyle, M.H. and Horwood, S.P. (1982), 'Application of multi-attribute utility theory to measure social preferences for health states', *Operations Research*, **30**, 1043–69.
- Torrance, G.W., Feeny, D., Furlong, D.H. et al. (1996), 'Multiattribute utility function for a comprehensive health status classification system', *Medical Care*, **34**, 702–22.
- Torrance, G.W., Thomas, W.H. and Sackett, D.L. (1972), 'A utility maximization model for evaluation of health care programs', *Health Services Research*, **7**, 118–33.
- Towers, I., Spencer, A. and Blazier, J. (2005), 'Healthy-year equivalents versus quality adjusted life years: the debate continues', *Expert Review of Pharmacoeconomics and Outcomes Research*, **5**, 245–54.
- Towse, A. (2008), 'Should NICE's threshold range for cost per QALY be raised? Yes', *British Medical Journal*, **338**, 268–9.
- Tsuchiya, A. (2000), 'QALYs and ageism: philosophical theories and age weighting', *Health Economics*, **9**, 57–68.
- Ubel, P.A., Loewenstein, G., Scanlon, D. and Kamlet, M. (1998), 'Value measurement in cost-utility analysis: explaining the discrepancy between rating scale and person trade-off elicitation', *Health Policy*, **43**, 33–44.
- United Nations Program on HIV/AIDS (UNAIDS) (2013), *Global Report: UNAIDS Report on the Global AIDS Epidemic 2013*, New York: UNAIDS.
- Usher, D. (2006), 'The marginal cost of public funds is the ratio of mean income to median income', *Public Finance Review*, **34**, 687–711.
- Vaillant, G.E. (1983), *The Natural History of Alcoholism*, Cambridge, MA: Harvard University Press.

- Van Hout, B.A. (1998), 'Discounting costs and effects: a reconsideration', *Health Economics*, **7**, 581–94.
- Vinod, H. (1988), 'Dynamic benefit–cost ratio criterion for practical sequential ranking to encourage cost control and self help', *Indian Economic Review*, **23**, 263–74.
- Viscusi, W.K. (1995), 'Discounting health effects for medical decisions', in F.A. Sloan (ed.), *Valuing Health Care*, New York: Cambridge University Press, pp. 125–47.
- Viscusi, W.K. and Aldy, J.E. (2003), 'The value of a statistical life: a critical review of market estimates throughout the world', *Journal of Risk and Uncertainty*, **27**, 5–76.
- Von Neuman, J. and Morgenstern, O. (1944), *The Theory of Games and Economic Behavior*, Princeton, NJ: Princeton University Press.
- Wagstaff, A. (1991), 'QALYs and the equity–efficiency trade-off', *Journal of Health Economics*, **10**, 21–41.
- Walter, S.D., Gafni, A. and Birch, S. (2007), 'Estimation, power and sample size calculations for stochastic cost and effectiveness analysis', *Pharmacoeconomics*, **25**, 455–66.
- Weiers, R.M. (2011), *Introduction to Business Statistics*, 7th edn, New York: Duxbury.
- Weimer, C. (1987), 'Optimal disease control through combined use of preventative and curative measures', *Journal of Development Economics*, **25**, 301–19.
- Weimer, D.L., Vining, A.R. and Thomas, R.K. (2009), 'Cost–benefit analysis involving addictive goods: contingent valuation to estimate willingness-to-pay for smoking cessation', *Health Economics*, **18**, 181–202.
- Weinstein, M.C. (1980), 'Estrogen use in postmenopausal women: costs, risks and benefits', *New England Journal of Medicine*, **303**, 308–16.
- Weinstein, M.C. (1995), 'From cost-effectiveness ratios to resource allocation', in F.A. Sloan (ed.), *Valuing Health Care*, New York: Cambridge University Press, pp. 77–97.
- Weinstein, M.C. and Stason, W.B. (1977), 'Foundations of cost-effectiveness analysis for health and medical practices', *New England Journal of Medicine*, **296**, 716–21.
- Weinstein, M.C., Siegel, J.E., Gold, M.R., Kamlet, M. and Russell, L.B. (1996), 'Recommendations of the panel on cost-effectiveness in health and medicine', *Journal of the American Medical Association*, **276**, 1253–8.
- Weintraub, W.S., Mauldin, P.D., Becker, E., Kosinski, A.S. and King III, S.B. (1995), 'A comparison of the costs of and quality of life after coronary artery disease', *Circulation*, **92**, 2831–40.
- Weisbrod, B.A. (1961), *Economics of Public Health*, Philadelphia, PA: University of Pennsylvania Press.
- Weisbrod, B.A. (1981), 'Benefit-cost analysis of a controlled experiment: treating the mentally ill', *The Journal of Human Resources*, **16**, 523–48.
- Weisbrod, B.A., Test, M.A. and Stein, L.I. (1980), 'Alternative to mental hospital treatment', *Archives of General Psychiatry*, **37**, 400–405.
- White, C.C., Koplan, J.P. and Orenstein, W.A. (1985), 'Benefits, risks and costs of immunization for measles, mumps and rubella', *American Journal of Public Health*, **75**, 739–44.
- Whittington, D., Matsui-Santana, O., Freiberger, J.J., Van Houtven, G. and Subhrendu, P. (2002), 'Private demand for a HIV/AIDS vaccine: evidence from Guadalajara, Mexico.' *Vaccine* **20**, 2585–91.



- Wikipedia (2012), 'Median household income', [http://en.wikipedia.org/wiki/Median\\_household\\_income](http://en.wikipedia.org/wiki/Median_household_income) (accessed 7 June 2014).
- Wildasin, D.E. (1991), 'The marginal cost of public funds with an aging population', in Dressen, E. and van Winden, F. (eds), *Fiscal Implications of an Aging Population*, Berlin: Springer-Verlag.
- Willan, A.R. and O'Brien, B.J. (1996), 'Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem', *Health Economics*, **5**, 297–305.
- Williams, A. (1997), 'Intergenerational equity: an exploration of the "fair innings" argument', *Health Economics*, **6**, 117–32.
- Williams, A. and Cookson, R. (2000), 'Equity in health', in A.J. Culyer and J.P. Newhouse (eds), *Handbook of Health Economics*, vol. 1B, Amsterdam: Elsevier, pp. 1863–910.
- Williams, J., Pacula, R.L., Chaloupka, F.J. and Wechsler, H. (2004), 'Alcohol and marijuana use among college students: economic complements of substitutes', *Health Economics*, **13**, 825–43.
- World Bank (1993), *World Development Report 1993*, New York: Oxford University Press.
- World Bank (2003), *World Development Report 2003*, New York: Oxford University Press.
- Worrall, J. (2007), 'Evidence in medicine and evidence-based medicine', *Philosophy Compass*, **2**, 981–1022.
- Yu, X. and Abler, D. (2010), 'Interactions between cigarette and alcohol consumption in rural China', *European Journal of Health Economics*, **11**, 151–60.
- Zarkin, G.A., Cates, S.C. and Bala, M.V. (2000), 'Estimating the willingness to pay for drug abuse treatment', *Journal of Substance Abuse Treatment*, **18**, 149–59.

